Capital Fund Management S.A. decreased its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 37.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,141 shares of the company's stock after selling 64,441 shares during the quarter. Capital Fund Management S.A. owned approximately 0.09% of Guardant Health worth $3,273,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of GH. R Squared Ltd acquired a new stake in Guardant Health during the 4th quarter valued at $26,000. SBI Securities Co. Ltd. acquired a new stake in shares of Guardant Health in the fourth quarter valued at $43,000. Kimelman & Baird LLC bought a new position in shares of Guardant Health in the fourth quarter valued at about $58,000. Quantbot Technologies LP acquired a new position in Guardant Health during the 4th quarter worth about $80,000. Finally, Jones Financial Companies Lllp grew its holdings in Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after acquiring an additional 817 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.
Guardant Health Trading Down 0.5 %
Shares of GH stock traded down $0.21 during trading hours on Friday, hitting $44.97. 1,843,910 shares of the company were exchanged, compared to its average volume of 2,136,744. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $50.89. The business has a 50 day moving average of $43.53 and a two-hundred day moving average of $36.21. The company has a market capitalization of $5.55 billion, a PE ratio of -12.63 and a beta of 1.45.
Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. On average, research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on GH shares. Canaccord Genuity Group upped their target price on shares of Guardant Health from $42.00 to $60.00 and gave the stock a "buy" rating in a research report on Monday, February 24th. Morgan Stanley lifted their target price on Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research note on Thursday, March 6th. Stifel Nicolaus boosted their target price on Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Stephens reiterated an "overweight" rating and issued a $55.00 price target on shares of Guardant Health in a report on Wednesday, March 26th. Finally, Piper Sandler boosted their price objective on Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Twenty analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $49.00.
View Our Latest Analysis on GH
About Guardant Health
(
Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Further Reading
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
